FELIQS INC.
Preclinical-stage biotechnology company originating from molecular pathobiology research at Kyushu University. Focused on discovery and preclinical development of therapeutics that modulate ferroptosis and oxidized-lipid pathways, with an emphasis on ophthalmology indications and progression toward IND-enabling studies and clinical trials.
Industries
N/A
Nr. of Employees
small (1-50)
FELIQS INC.
Products
FLQ-101
Preclinical development candidate indicated for retinopathy of prematurity; development status listed in preclinical pipeline.
FLQ-105
Preclinical development candidate indicated for geographic atrophy and wet age-related macular degeneration; administered orally in development summaries.
FLQ-101
Preclinical development candidate indicated for retinopathy of prematurity; development status listed in preclinical pipeline.
FLQ-105
Preclinical development candidate indicated for geographic atrophy and wet age-related macular degeneration; administered orally in development summaries.
Expertise Areas
- Ferroptosis-targeted therapeutic discovery
- Preclinical development and IND enabling
- Ophthalmology drug development
- Clinical trial planning and regulatory strategy
Key Technologies
- Ferroptosis modulation
- Oxidized lipid biology
- Preclinical pharmacology
- IND-enabling study design